Table 2.
Colonization status by serotype prior to first PCV dose |
Colonization status by serotype only prior to 2nd and/or 3rd PCV dose |
|||||
---|---|---|---|---|---|---|
Serotype 6B carriers vs. non-carriers |
6B-positive (n=10) |
6B-negative | P-value | 6B-positive (n=13) |
6B-negative until 3rd PCV dose |
P-value |
Anti-6B: n with ≥0.35 μg/ml (%) | 4 (40.0) | 427/ 472 (90.5) | <0.0001 | 11 (84.6) | 416/ 459 (90.6) | 0.615 |
Anti-19F: n with ≥0.35 μg/ml (%) | 10 (100.0) | 465/ 469 (99.1) | NE* | 13 (100) | 452/ 456 (99.1) | NE |
Anti-23F: n with ≥0.35 μg/ml (%) | 9 (90.0) | 455/ 471 (96.6) | 0.436 | 13 (100) | 442/ 458 (96.5) | 0.99 |
Serotype 19F carriers vs. non-carriers |
19F-positive (n=9) | 19F-negative | P-value | 19F-positive (n=17) |
19F-negative until 3rd PCV dose |
P-value |
---|---|---|---|---|---|---|
Anti-6B: n with ≥0.35 μg/ml (%) | 8 (88.9) | 423/473 (89.4) | 0.877 | 15 (88.2) | 408/456 (89.6) | 0.946 |
Anti-19F: n with ≥0.35 μg/ml (%) | 8 (88.9) | 467/470 (99.4) | NE | 16 (94.1) | 451/453 (99.6) | NE |
Anti-23F: n with ≥0.35 μg/ml (%) | 9 (100.0) | 455/472 (96.4) | NE | 17 (100.0) | 438/455 (96.3) | NE |
Serotype 23F carriers vs . non-carriers |
23F-positive (n=11) | 23F-negative | P-value | 23F-positive (n=13) |
23F-negative until 3rd PCV dose |
P-value |
---|---|---|---|---|---|---|
Anti-6B: n with ≥0.35 μg/ml (%) | 10 (90.9) | 421/471 (89.4) | 0.960 | 11 (84.6) | 410/458 (89.5) | 0.378 |
Anti-19F: n with ≥0.35 μg/ml (%) | 11 (100.0) | 464/468 (99.1) | NE | 13 (100) | 451/455 (99.1) | NE |
Anti-23F: n with ≥0.35 μg/ml (%) | 9 (81.8) | 455/470 (96.8) | 0.015 | 9 (69.2) | 446/457 (97.6) | <0.0001 |
Rows in shaded grey: antibodies against the carried serotype.
NE: The reporting of p-values as NE (not estimable) was due to either quasi-complete separation or complete separation which is a common issue in the Logistic Regression analysis. These p-values would generally have been ≥0.95.